Hims & Hers Health (NYSE: HIMS) continues to be a volatile stock.
The stock’s value has been cut in half over the past year, but at one point this year, it had doubled off its lows
Following its Q1 earnings announcement on May 11, the stock was once again heading lower. Let’s take a closer look at the telehealth company’s results and prospects to see if this dip is a buying opportunity. Hims is dealing with margin compression While Hims management raised its revenue outlook for the year, it significantly lowered its adjusted EBITDA guidance.
It now expects revenue to range from $2.8 billion to $3 billion, with adjusted EBITDA of between $275 million and $350 million. That compares to an earlier forecast of 2026 revenue between $2.7 billion and $2.9 billion, with adjusted EBITDA of between $300 million and $375 million. The revised guidance stems from the company’s pivot to branded weight-loss drugs, in particular Novo Nordisk’s Wegovy.